University of South Florida

King Abdullah University of Science and Technology

Transform Pharmaceuticals, Inc.

University of Michigan

Mcneil-ppc, Inc.

Michael John Zaworotko

Mohamed Eddaoudi

Patrick Nugent

Youssef Belmabkhout

Stephen Burd

Matthew Lynn Peterson

Osama Shekhah

Roland Douglas Shytle

Magali Bourghol Hickey

Ryan Luebke

Padmini Kavuru

Brian Moulton

Tien Teng Ong

Örn Almarsson

Heather Clarke

Nair Rodriguez-Hornedo

Arora Kapildev

Lissette Marshall

Twarita Pujari

Tanise Shattock

Julius F Remenar

Adam John Smith

Mark Tawa

Naga Duggirala

Jarrod F Eubank

Jennifer McMahon

Sameh Elsaidi

Till Bousquet

Lukasz Wojtas

Farid Nouar

Sheshanka Kesani

Vanessah Rhodus

Mona H Mohamed

Tranhha Nguyen

Ryan N Cantwell

Oern Almarsson

Matthew Peterson

Embodiments of the present disclosure provide for metal-organic materials (MOMs), systems that exhibit permanent porosity and using hydrophobic MOMs to separate components in a gas, methods of separating COfrom a gas, and the like.

[object Object]

Co-crystals comprising at least one nutraceutical compound and at least one co-crystal former with or without impurities. These co-crystals may be included in compositions (optionally also including other components such as pharmaceutically acceptable excipients, other nutritional supplements, etc.) having utility as pharmaceuticals, nutraceuticals, nutritional supplements, and foodstuffs.

Nutraceutical co-crystal compositions

The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to binary phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions.

Multiple-component solid phases containing at least one active pharmaceutical ingredient

2:1 cocrystals of amino acids and Li+ salts crystallize from hot water to afford water stable cationic networks based upon tetrahedral lithium cations: bilayered square grids, a lithium zeolitic metal-organic material (LiZMOM) and several lithium diamondoid metal-organic materials (LiDMOMs). The compositions may be used as a pharmaceutical for the treatment of suicidality and other disorders that require lithium to penetrate the blood brain barrier and exert therapeutic effects in the CNS. Advantageously, the novel cocrystal forms described herein may be used to lower the oral dose required to achieve therapeutic concentrations of lithium in the brain, thus reducing the peripheral toxicity and potentially broadening the therapeutic index in comparison to conventional lithium forms.

Lithium cocrystal compositions

Metal-organic materials (MOMs) for CO2 absorption and methods of using MOMs

Embodiments of the present disclosure provide for multi-component metal-organic materials (MOMs), systems including the MOM, systems for separating components in a gas, methods of separating polarizable gases from a gas mixture, and the like.

Metal-organic materials (MOMs) for adsorption of polarizable gases and methods of using MOMs

Embodiments of the present disclosure provide for multi-component metal-organic materials (MOMs) systems that exhibit permanent porosity and using MOMs to separate components in a gas mixture, methods of separating polarizable gases from a gas mixture, and the like.

Metal-organic materials (MOMS) for polarizable gas adsorption and methods of using MOMS

Embodiments of the present disclosure provide for hydrophobic multi-component metal-organic materials (MOMs) (also referred to as 'hydrophobic MOM'), systems that exhibit permanent porosity and using hydrophobic MOMs to separate components in a gas, methods of separating COfrom a gas, and the like.

Crystalline epigallocatechin-3-gallate compositions and methods of use.

Epigallocatechin-3-gallate crystal compositions

Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided.

Pharmaceutical forms, and methods of making and using the same

The present invention generally relates to supramolecular assemblies and their modes of synthesis. The supramolecular assemblies include a 1:8 ratio of a supermolecular polyhedral building block and a triangular molecular building block, the supermolecular polyhedral building block having points of extension corresponding to the vertices of a rhombicuboctahedron for linking the supermolecular polyhedral building block to the triangular building block.

Supramolecular assemblies and building blocks

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

Pharmaceutical co-crystal compositions

Growing community of inventors

Tampa, FL, United States of America

Michael John Zaworotko